Association of Epirubicin, Etoposide and Cisplatin in Gastric Cancer

Publisher Website
Google Scholar
Abstract
Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3 ± 7%); 9 patients had partial response (31 ± 17%); 5 patients (17±14%) were considered stable (S) and 14 (48 ± 18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.

This publication has 0 references indexed in Scilit: